Compare Quest Diagnostics Inc (DGX) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Fortinet Inc — how do they compare? Quest Diagnostics Inc trades at $231.65 (market cap $25.48B), while Fortinet Inc trades at $194.44 (market cap $138.75B). The key difference: Fortinet Inc is far larger — about 5.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Fortinet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Fortinet Inc for 72 Days on average.
| DGX | FTNT | |
|---|---|---|
Market Cap | $25.48B | $138.75B |
Volume | 941,866 | 2,956,908 |
Sector | Health | Technology |
52-Week High | $247.45 | $191.27 |
52-Week Low | $173.49 | $75.23 |
Typical Hold Time | 56 Days | 72 Days |
Enterprise Value | $31.23B | $135.17B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Fortinet (FTNT) trades at $193.44, up 2.2% today and near its 52-week high, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growing from $4.4B in 2022 to $6.8B in 2025, maintaining high profit margins above 28%. Recent quarterly earnings have consistently beaten expectations, and the company is positioned to benefit from AI-driven cybersecurity demand.
The outlook remains positive with raised 2026 guidance and strong platform adoption, though elevated valuation ratios (P/E 66.82, P/S 18.79) present risks. Analyst consensus is mixed with 42% buy ratings but a price target below current levels. Key risks include competitive pressures and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
